Navigation Links
Study on effects of resveratrol and quercetin on inflammation and insulin resistance
Date:12/23/2010

A study was carried out to examine the extent to which quercetin and trans-resveratrol (RSV) prevented inflammation or insulin resistance in primary cultures of human adipocytes treated with tumor necrosis factor-a (TNF-a)an inflammatory cytokine elevated in the plasma and adipose tissue of obese, diabetic individuals. Cultures of human adipocytes were pretreated with quercetin and trans-RSV followed by treatment with TNF-a. Subsequently, gene and protein markers of inflammation and insulin resistance were measured. The authors report that quercetin, and to a lesser extent trans-RSV, attenuated the TNF-ainduced expression of inflammatory genes such as interleukin (IL)-6, IL-1b, IL-8, and monocyte chemoattractant protein-1 (MCP-1) and the secretion of IL-6, IL-8, and MCP-1.

Forum members were concerned about certain aspects of the study, especially the extrapolation of in vitro results to in vivo situations. The in vitro conditions the authors describe are minimally representative of an in vivo condition. In vivo, after consumption of quercetin or resveratrol, these compounds undergo extensive metabolism, leading to glucuronidated, sulphated or methylated compounds. In a previous study, quercetin 3-glucoside was transformed to 3,4-dihydroxyphenylacetic acid, acetate and butyrate in cells from human gut; only 3'-methylquercetin has been detected in human plasma, present at a concentration of 0.1 to 0.2 M after 3 h. The authors of the current paper are using concentrations up to 60 M, concentrations which have not been found in vivo.

There were also concerns with the work on cell uptake of quercetin and resveratrol. Primary adipocytes were incubated with the polyphenols, but it is not clear whether or not the concentrations used were subtoxic. Our current knowledge is limited about local concentration of the molecules we are studying in subcellular compartments, their interaction with alternative targets, and eventually their transformation into products that could be more or less active on a given specific pathway. The real difficult and important issue is the identification of a reasonable convergence -- if not agreement -- between data originating from extremely distant approaches. In this case, the notion that metabolic diseases are related to a homeostatic imbalance in adipose tissue, linked to a different redox status, linked to activation of specific pathways, and that different redox sensitive polyphenols do have a protective effect, encompasses the evidence produced by extremely distant approaches.

From a clinical point of view, the role of phytochemicals acting as antioxidants and anti-inflammatory agents could be extremely important in inflammation-associated chronic conditions such as cardiovascular disease, diabetes, and cancer. Quercetin and resveratrol may indeed play an important role in this regard, and need to be investigated further to establish the clinical importance of natural dietary compounds in the prevention of chronic degenerative conditions.


'/>"/>

Contact: R. Curtis Ellison
ellison@bu.edu
508-333-1256
Boston University Medical Center
Source:Eurekalert

Related biology news :

1. Study shows drifting fish larvae allow marine reserves to rebuild fisheries
2. New study to examine effects and threats of climate change on plants and animals in Andes
3. Fruit fly study digs deeper into poorly understood details of forming embryos
4. Sea-level study brings good and bad news to Chesapeake Bay
5. Dodds contributes to new national study on nitrogen water pollution
6. New study examines immunity in emerging species of a major mosquito carrer of malaria
7. New study focuses on nitrogen in waterways as cause of nitrous oxide in the atmosphere
8. SU biologist partners with National Park Service to study bison grazing in Yellowstone
9. Despite damage, membrane protein structure can be seen using new X-ray technology, study reveals
10. CSHL study finds that 2 non-coding RNAs trigger formation of a nuclear subcompartment
11. Consortium studying mathematical modeling of influenza infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2016)... Dec. 16, 2016   IdentyTechSolutions America LLC ... products and solutions and a cutting-edge manufacturer of ... it is offering seamless, integrated solutions that comprise ... products. The solutions provide IdentyTech,s customers with combined ... facilities from crime and theft. "We ...
(Date:12/16/2016)... -- The global wearable medical device market, in terms of value, ... 5.31 billion in 2016, at a CAGR of 18.0% during the ... ... medical devices, launch of a growing number of smartphone-based healthcare apps ... providers, and increasing focus on physical fitness. Furthermore, ...
(Date:12/15/2016)... Dec. 15, 2016   WaferGen Bio-systems, Inc. ... technology company, announced today that on December 13, 2016, ... of The Nasdaq Stock Market LLC which acknowledged that, ... of WaferGen,s common stock had been at $1.00 or ... regained compliance with Listing Rule 5550(a)(2) of the Nasdaq ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... ... January 19, 2017 , ... ... for pharmaceutical research and development (R&D), today announced the launch of ... and interpretation for the rapidly evolving field of precision medicine. , ...
(Date:1/19/2017)... Jan. 19, 2017  ArmaGen, Inc., today announced ... Ph.D., as chief executive officer, as well as ... brings to ArmaGen more than 17 years of ... development of biotherapeutics and pharmaceuticals. ... diverse experience and skillset necessary to lead ArmaGen ...
(Date:1/19/2017)... Yorba Linda, Ca (PRWEB) , ... January 18, ... ... interactive virtual events for tech innovators, engineers, and scientists from around the world, ... Corporate American News. The awards program is based entirely on merit and decided ...
(Date:1/19/2017)... 2017 The global biotechnology services outsourcing ... by 2025, according to a new report by ... adaptive of the function of outsourcing certain clinical ... the services outsourced, clinical trial management and contract ... Johnson was the first pharmaceutical company to outsource ...
Breaking Biology Technology: